CN101732290A - Stable solid formulation of egualen sodium - Google Patents
Stable solid formulation of egualen sodium Download PDFInfo
- Publication number
- CN101732290A CN101732290A CN200910226048A CN200910226048A CN101732290A CN 101732290 A CN101732290 A CN 101732290A CN 200910226048 A CN200910226048 A CN 200910226048A CN 200910226048 A CN200910226048 A CN 200910226048A CN 101732290 A CN101732290 A CN 101732290A
- Authority
- CN
- China
- Prior art keywords
- sodium
- egualen
- solid formulation
- weight portion
- egualen sodium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention provides a solid formulation of egualen sodium, which is mixed with more than one additive selected from polyvidon, a derivative thereof and alkali additive. The polyvidon derivative is preferably one component described as follows: an alkali inorganic compound selected from magnesium carbonate, calcium carbonate, magnesium hydroxide, magnesium oxide, sodium carbonate, sodium bicarbonate and sodium hydroxide; or an alikali organic compound selected from arginine, lysine, histidine and ornithine. Additionally, the invention further relates to the solid formulation of egualen sodium which is mixed with enough amount of alkali additive. The enough amount is an amount which causes pH value of the aqueous dispersion to obtain a value higher than 7 when the solid formulation is dispersed into water with a concentration of 1W/V%. The solid formulation of egualen sodium restrains the generation of egualen sodium decomposition product and is a stable formulation.
Description
Technical field
The present invention relates to suppress the solid formulation of egualen sodium that egualen sodium decomposes.
Background technology
Egualen sodium [chemical name: 3-ethyl-7-isopropyl-1-Sodium Azulenesulfonate 1/3 hydrate] has excellent gastric mucosal protective effect by oral administration, and its curative as gastric ulcer etc. is excellent medicine (Japan's special permission bulletin communique: the special fair 1-49259 communique of Japan).All the time, the Sodium Azulenesulfonate that has identical mother nucleus structure with egualen sodium is used to treat various diseases associated with inflammation, gastritis, gastric ulcer etc., but because its instability, so when making preparation, must take some measures to guarantee its stability people's motion has been arranged for this reason the whole bag of tricks.Relevant stabilization method when Sodium Azulenesulfonate or azulene derivatives are made preparation, people's motion has been arranged following method: for example wrap method (day disclosure special permission communique: Japanese kokai publication sho 56-30927 communique) that connects with cyclodextrin, together carry out spray drying or cryodesiccated method (Japanese kokai publication hei 1-50225 communique) separately or with macromolecular compound, with the seal-packed method of deoxidizer (Japanese kokai publication sho 59-176247 communique), the method (Japanese kokai publication hei 1-121216 communique) of mixing edetic acid and its esters, the method (TOHKEMY 2005-154334 communique) of mixing polyhydric alcohol such as propylene glycol, the method of mixed surfactant (Japan's special permission communique: No. 2505513 communique of Japan's special permission), mix the method (TOHKEMY 2003-128537 communique) of xanthine etc.
Though egualen sodium has the azulene ring identical with Sodium Azulenesulfonate as mother nucleus structure, comparing with Sodium Azulenesulfonate is very stable chemical compound.But, though egualen sodium is highly stable, can under high temperature, high humidity or exposure, still confirm to have generated the analyte from egualen sodium of trace, egualen sodium is made preparation after, need implement the method that suppresses to generate analyte during keeping.
Summary of the invention
Invent problem to be solved
The object of the present invention is to provide solid formulation of egualen sodium that the analyte that suppressed egualen sodium generates, i.e. stable solid formulation of egualen sodium.
Solve the method for problem
The inventor etc. further investigate in order to achieve the above object repeatedly, and the result is surprised to find that: by mixing the polyvidone or derivatives thereof, can suppress the generation from the analyte of egualen sodium.Also find in addition:, can suppress generation from the analyte of egualen sodium by the mixed-alkali additive.The present invention is based on above-mentioned cognition and establish.
That is, the present invention relates to solid formulation of egualen sodium, said preparation has mixed more than one the additive that is selected from polyvidone and derivant and alkalinity additive and has made.The preferred polyvinylpolypyrrolidone of polyvidone derivant.As alkalinity additive, for example can use alkaline inorganic compound, alkaline organic compound.And alkaline inorganic compound preferably uses and is selected from magnesium carbonate, calcium carbonate, magnesium hydroxide, magnesium oxide, sodium carbonate, sodium bicarbonate and the sodium hydroxide one or more.Alkaline organic compound preferably uses and is selected from arginine, lysine, histidine and the ornithine one or more.In addition, the invention still further relates to solid formulation of egualen sodium, said preparation has mixed the above-mentioned alkalinity additive of q.s to be made, and described q.s is meant when being dispersed in water with the concentration of 1W/V% solid preparation, makes the pH value of gained aqueous dispersions reach amount more than 6.5.
The best mode that carries out an invention
Egualen sodium among the present invention for example can utilize Japan special fair 1-49259 communique in disclosed known method prepare.The polyvidone that uses among the present invention be N-vinyl-2-Pyrrolidone polymer, be polyvinylpyrrolidone.The example of polyvidone derivant has polyvinylpolypyrrolidone.Polyvinylpolypyrrolidone is the cross-linking agent of polyvinylpyrrolidone.The example of the alkalinity additive that uses among the present invention has: alkaline inorganic compound and alkaline organic compound.The object lesson of alkaline inorganic compound has: magnesium carbonate, calcium carbonate, magnesium hydroxide, magnesium oxide, sodium carbonate, sodium bicarbonate, sodium hydroxide etc., preferably use sodium bicarbonate.The object lesson of alkaline organic compound has: basic amino acid, be general chemical compound in medicine, the food such as arginine, lysine, histidine, ornithine, preferably use arginine, lysine.Above-claimed cpd can use one or more.
The combined amount of polyvidone, its derivant or alkalinity additive will suitably be selected according to the content of egualen sodium in the preparation.An example as combined amount, can be listed below: with respect to 1 weight portion egualen sodium in the preparation, polyvinylpolypyrrolidone is 0.1～3 weight portion, preferred 0.2～0.5 weight portion, polyvidone is 0.1～3 weight portion, preferred 0.2～0.5 weight portion, and alkalinity additive is about 0.005～1 weight portion, preferred 0.05～0.1 weight portion.During the mixed-alkali additive, preferably mix the alkalinity additive of q.s, described q.s is meant when the solid preparation that will make is dispersed in the water with the concentration of 1W/V%, makes the pH value of gained aqueous dispersions reach amount more than 6.5.Further preferred the mixing is enough to make pH value to reach the alkalinity additive of the amount more than 7.In the present invention, by polyvidone or derivatives thereof and alkalinity additive are mixed in the lump, can further improve the stability of solid formulation of egualen sodium.
In preparation of the present invention, can use the additive that is generally used for oral Preparation as other blending constituents.So long as the composition that can be added in the medicine gets final product, be not particularly limited, for example can admixed excipients, disintegrating agent, binding agent, lubricant, surfactant, stabilization agent, plasticizer, correctives, coating materials, coloring agent etc.
The example of excipient has: alphalysed starch, the part alphalysed starch, silicon dioxide, Citric acid calcium, aluminosilicate magnesium, calcium silicates, magnesium silicate, light silicon anhydride, crystalline cellulose, crystalline cellulose-sodium carboxymethyl cellulose, synthetic aluminium silicate, synthetic hydrotalcite, wheaten starch, rice starch, gelatin, calcium carbonate, corn starch, trehalose, sucrose, potato starch, glucose, the lactose hydrate, D-mannitol, Lactis Anhydrous, calcium phosphate dibasic anhydrous, positive aluminosilicate magnesium, methylcellulose, calcium hydrogen phosphate, dibastic sodium phosphate etc.Examples of disintegrants has: alphalysed starch, carboxymethyl starch sodium, carmellose, carboxymethylcellulose calcium, sodium carboxymethyl cellulose, agar powder, cross-linking sodium carboxymethyl cellulose, crystalline cellulose, crystalline cellulose-sodium carboxymethyl cellulose, low-substituted hydroxypropyl cellulose, dextrin, corn starch, part alphalysed starch, positive aluminosilicate magnesium etc.
The example of binding agent has: ethyl cellulose, caramel, carmellose, guar gum, wheaten starch, rice starch, gelatin, low-substituted hydroxypropyl cellulose, corn starch, potato starch, paraffin, hydroxyethyl-cellulose, hydroxyethylmethyl-cellulose, hydroxypropyl starch, hydroxypropyl cellulose, hydroxypropyl emthylcellulose, part alphalysed starch, polyvinyl alcohol, Polyethylene Glycol, methylcellulose, wax etc.The example of lubricant has: Brazil wax, glycerol, magnesium silicate, light silicon anhydride, liquid paraffin,light, dimethyl polysiloxane, octadecanol, stearic acid, magnesium stearate, calcium stearate, Pulvis Talci, liquid paraffin etc.Lubricant pestle in tabletting obstacles such as sticking, layering, sliver and the tabletting step or adhering to of mortar normally occur and is added on composition in the moulding material for the flowability of improving the moulding material of making tablet or for the tablet that prevents manufacturing, but also can be coated on tablet surface, to improve the wettability of tablet.
The example of surfactant has: alkyl allyl polyether alcohol, cholesterol, glycerol monostearate, sucrose fatty acid ester, squalane, octadecanol, spermol, sorbitan fatty acid esters, Sorbitan Sesquioleate, polyoxyethylene hydrogenated Oleum Ricini, polyoxyethylene octadecyl ether, the polyoxyethylene sorbitan monolaurate, polysorbate, Polyethylene Glycol, single oleic acid sorbitan, the monostearate sorbitan, sodium lauryl sulphate, Brij30 etc.The example of stabilization agent has: ascorbic acid, albumin, edetate sodium, tocopherol etc.The example of plasticizer has: dioctyl adipate, triethyl citrate, fatty acid glyceride, glycerol, dimethyl polysiloxane, medium-chain fatty acid triglyceride, concentrated glycerin, Oleum Ricini, dioctyl phthalate, propylene glycol, Polyethylene Glycol, liquid paraffin etc.
As correctives, can use aspartame, sweet tea powder, aminoalkyl methacrylate copolymer, erythritol, orange, cocoa powder, fructose, reduction Fructus Hordei Germinatus sucrose solution maltose, Radix Glycyrrhizae powder, xylitol, Citric acid calcium, citric acid hydrate, L-glutaminate, L-glutamic acid, grapefruit extract, glucide, cyclodextrin, tartaric acid, Flos Chrysanthemi to extract general correctives in purification thing, purification sucrose, purification Mel, D-Sorbitol, trehalose, sucrose, glucose, maltose alcohol, D-mannitol, menthol, green tea powder, Fructus Citri Limoniae wet goods medicine, the food.The example of coloring agent has: iron oxide yellow, yellow iron sesquioxide, iron oxide brown, white carbon black, iron oxide black, titanium oxide, edible blue No. 1, edible yellow No. 4, edible yellow No. 5, edible red No. 2, edible red No. 3, edible red No. 102, copper chlorophyll, phenol red, gentian violet, peacock green, methylene blue etc.
As the dosage form of preparation of the present invention, can adopt powder, granule (comprising coated granule etc.), granula subtilis, tablet (plain sheet, coated tablet, coated tablet, chewable tablet, oral cavity disintegration tablet etc.), hard capsule, soft capsule, pill, lozenge, dry syrup, solution, elixir, spirits, syrup, liniment etc. as preparation and known various solid dosage forms.
For powder, granule, granula subtilis, tablet, capsule, for example can utilize and the 15th correct that pulverizing, classification, mixing, the refining put down in writing in the preparation general provisions of Pharmacopeia of Japan are closed, the conventional method in these technical fields such as method of pelletize, drying, granulate, tabletting etc. is prepared.Promptly, preparation is during tablet, polyvinylpolypyrrolidone, polyvidone or alkalinity additive joined in excipient, binding agent, disintegrating agent, the correctives etc. mix, and adds egualen sodium solution again to make granule, carry out tabletting to wherein adding lubricant etc. afterwards, make tablet.Perhaps, can also wait by compressing dry granulation to prepare, promptly, carry out tabletting only with egualen sodium and polyvinylpolypyrrolidone, polyvidone or alkalinity additive and the mixing of other additives.Prilling process is not particularly limited, wet granulation, non-slurry pelletizings such as fluidized bed prilling, stirring-granulating, high-speed stirred pelletize, extruding pelletization are for example arranged.Preparation method to tablet is not particularly limited, and for example can use rotary tablet machine to carry out tabletting.Tablet machine can also use the tablet machine that possesses the device of application of lubricating on pestle and mortar.
Can utilize known method to carry out coating to tablet, granule.The example of coating materials has: the aminoalkyl methacrylate copolymer, ethyl cellulose, Opadry, Brazil wax, CVP Carbopol ETD2050, carboxymethylcellulose calcium, triethyl citrate, glycerol, fatty acid glyceride, titanium oxide, dimethyl polysiloxane, sucrose, gelatin, Pulvis Talci, paraffin, hydroxypropyl emthylcellulose, hydroxypropylmethyl cellulose phthalate, dibutyl phthalate, propylene glycol, polyoxyethylene hydrogenated Oleum Ricini, polysorbate, Polyethylene Glycol, Pioloform, polyvinyl acetal diethyl amino yl acetate, methacrylic acid copolymer, methylcellulose, Brij30 etc.And, when being tablet, can also make oral cavity disintegration tablet, chewable tablet etc. by mixing various disintegrating agents.
Solid formulation of egualen sodium of the present invention demonstrates excellent gastric mucosa injury and forms inhibitory action, ulcer healing facilitation etc., can be used for the treatment of gastric ulcer.When solid formulation of egualen sodium of the present invention being used for the treatment of gastric ulcer etc., can make various dosage forms in a manner described, carry out oral administration.Its dosage was preferably 30mg/ days in the about 15～60mg/ of egualen sodium days.
Below, further describe the present invention by embodiment and comparative example, but scope of the present invention is not subjected to any qualification of these embodiment and comparative example.
Embodiment 1
Egualen sodium joined in 50% the ethanol, stir, dissolving, make the egualen sodium solution of 0.33g/mL.133 weight portion corn starchs, 2 weight portion hydroxypropyl celluloses and 10 weight portion polyvinylpolypyrrolidone are mixed, add above-mentioned egualen sodium solution (containing 15 weight portion egualen sodiums) afterwards, pelletize.With gained particle drying, granulate, use the tablet machine compression molding afterwards, make tablet.
Embodiment 2
133 weight portion corn starchs, 2 weight portion hydroxypropyl celluloses and 10 weight portion polyvidones are mixed, add the egualen sodium solution (containing 15 weight portion egualen sodiums) of preparation among the embodiment 1 afterwards, pelletize.With gained particle drying, granulate, use the tablet machine compression molding afterwards, make tablet.
Embodiment 3
143 weight portion corn starchs, 2 weight portion hydroxypropyl celluloses, 10 weight portion crystalline celluloses, 5 weight portion polyvinylpolypyrrolidone and 5 weight portion polyvidones are mixed, add the egualen sodium solution (containing 15 weight portion egualen sodiums) of preparation among the embodiment 1 afterwards, pelletize.With gained particle drying, granulate, use the tablet machine compression molding afterwards, make tablet.
Embodiment 4
132 weight portion corn starchs, 2 weight portion hydroxypropyl celluloses and 1 weight portion sodium bicarbonate are mixed, add the egualen sodium solution (containing 15 weight portion egualen sodiums) of preparation among the embodiment 1 afterwards, pelletize.With gained particle drying, granulate, use the tablet machine compression molding afterwards, make tablet.
Embodiment 5
132 weight portion corn starchs, 2 weight portion hydroxypropyl celluloses and 5 weight portion sodium bicarbonate are mixed, add the egualen sodium solution (containing 15 weight portion egualen sodiums) of preparation among the embodiment 1 afterwards, pelletize.With gained particle drying, granulate, use the tablet machine compression molding afterwards, make tablet.
Embodiment 6
140 weight portion corn starchs, 2 weight portion hydroxypropyl celluloses, 10 weight portion crystalline celluloses, 5 weight portion polyvinylpolypyrrolidone, 5 weight portion polyvidones and 1 weight portion sodium bicarbonate are mixed, add the egualen sodium solution (containing 15 weight portion egualen sodiums) of preparation among the embodiment 1 afterwards, pelletize.With gained particle drying, granulate, use the tablet machine compression molding afterwards, make tablet.
Embodiment 7
140 weight portion corn starchs, 2 weight portion hydroxypropyl celluloses, 10 weight portion crystalline celluloses and 1 weight portion lysine are mixed, add the egualen sodium solution (containing 15 weight portion egualen sodiums) of preparation among the embodiment 1 afterwards, pelletize.With gained particle drying, granulate, use the tablet machine compression molding afterwards, make tablet.
Embodiment 8
140 weight portion corn starchs, 2 weight portion hydroxypropyl celluloses, 10 weight portion crystalline celluloses and 1 weight portion arginine are mixed, add the egualen sodium solution (containing 15 weight portion egualen sodiums) of preparation among the embodiment 1 afterwards, pelletize.With gained particle drying, granulate, use the tablet machine compression molding afterwards, make tablet.
Comparative example 1
133 weight portion corn starchs, 2 weight portion hydroxypropyl celluloses and 10 weight portion crystalline celluloses are mixed, add the egualen sodium solution (containing 15 weight portion egualen sodiums) of preparation among the embodiment 1 afterwards, pelletize.With gained particle drying, granulate, use the tablet machine compression molding afterwards, make tablet.
Experimental example 1
The tablet that obtains in embodiment and the comparative example is carried out stability test.In this test, the tablet that obtains in embodiment and the comparative example was preserved 5 days under the preservation condition of following condition 1～3.Generate various analog because of egualen sodium decomposes, preserve after 5 days, use high performance liquid chromatograph to measure the total content (total content of analog: % (quality)) of the analog that generates by the egualen sodium decomposition.Measurement result sees Table 1.In addition, take by weighing the tabletting powder of 1 part, add entry, the aqueous dispersions of preparation 1W/V% is measured its pH value.The results are shown in Table 1.
[preservation condition]
Condition 1
Preservation condition: room temperature, dark place
Manner of packing: vial sealing
Condition 2
Preservation condition: 50 ℃, dark place
Manner of packing: vial sealing
Condition 3
Preservation condition: 50 ℃, 75%RH, dark place
Manner of packing: vial is open
Compare with the preparation of comparative example, the preparation of embodiment 1～3 that has mixed polyvinylpolypyrrolidone, polyvidone is decomposed by egualen sodium under any condition and the analog total amount that produces is all few, hence one can see that: by mixing polyvinylpolypyrrolidone, polyvidone, come the growing amount of the analyte of the egualen sodium in the self-preparing agent to reduce.In addition, compare with comparative example, the preparation of embodiment 4,5 that has mixed alkalinity additive and be sodium bicarbonate is decomposed by egualen sodium under any condition and the analog total amount that produces is all few, and hence one can see that: come the growing amount of the analyte of the egualen sodium in the self-preparing agent to reduce.And, having mixed the preparation of the embodiment 6 of polyvinylpolypyrrolidone, polyvidone and sodium bicarbonate compares with the preparation of independent blended embodiment 1～5 respectively, the analog total amount that is produced by the egualen sodium decomposition is few, and hence one can see that: come the growing amount of the analyte of the egualen sodium in the self-preparing agent to reduce.Compare with comparative example, the preparation that has added alkalinity additive and be lysine or arginic embodiment 7,8 is decomposed by egualen sodium under any condition and the total amount of the analog that produces is all few, and hence one can see that: come the growing amount of the analyte of the egualen sodium in the self-preparing agent to reduce.
The invention effect
Be selected from more than one additive of PVP and derivative and alkalinity additive by mixing, the generation from the analyte of egualen sodium is inhibited, can obtain stable solid formulation of egualen sodium. And, by mixing in the lump PVP and derivative thereof and alkalinity additive, can further improve the stability of solid formulation of egualen sodium.
Claims (6)
1. solid formulation of egualen sodium is characterized in that: be mixed with more than one the additive that is selected from polyvidone and derivant and alkalinity additive in the said preparation.
2. the described solid formulation of egualen sodium of claim 1, wherein the polyvidone derivant is a polyvinylpolypyrrolidone.
3. claim 1 or 2 described solid formulation of egualen sodium, wherein alkalinity additive is to be selected from more than one of alkaline inorganic compound and alkaline organic compound.
4. the described solid formulation of egualen sodium of claim 3, wherein alkaline inorganic compound is to be selected from one or more of magnesium carbonate, calcium carbonate, magnesium hydroxide, magnesium oxide, sodium carbonate, sodium bicarbonate and sodium hydroxide.
5. the described solid formulation of egualen sodium of claim 3, wherein alkaline organic compound is to be selected from one or more of arginine, lysine, histidine and ornithine.
6. the described solid formulation of egualen sodium of claim 1 is characterized in that: the combined amount of alkalinity additive makes the pH value of gained aqueous dispersions reach enough amounts more than 6.5 when being dispersed in the water with the concentration of 1W/V% solid preparation.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008-289702 | 2008-11-12 | ||
| JP2008289702A JP5465867B2 (en) | 2008-11-12 | 2008-11-12 | Stable eguarene sodium solid formulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101732290A true CN101732290A (en) | 2010-06-16 |
| CN101732290B CN101732290B (en) | 2013-08-28 |
Family
ID=42278565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009102260483A Expired - Fee Related CN101732290B (en) | 2008-11-12 | 2009-11-12 | Stable solid formulation of egualen sodium |
Country Status (4)
| Country | Link |
|---|---|
| JP (1) | JP5465867B2 (en) |
| KR (1) | KR101627860B1 (en) |
| CN (1) | CN101732290B (en) |
| HK (1) | HK1142806A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102861337B (en) * | 2012-03-26 | 2017-08-11 | 北京阜康仁生物制药科技有限公司 | One kind contains solid formulation of egualen sodium |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6133702B2 (en) * | 2013-06-18 | 2017-05-24 | 紀州技研工業株式会社 | Ink jet ink, method for producing the same, and method for using the same |
| JP6060102B2 (en) * | 2014-03-13 | 2017-01-11 | 紀州技研工業株式会社 | Ink jet ink, method for producing the same, and printing method using the ink jet ink |
| JP6426115B2 (en) * | 2016-04-06 | 2018-11-21 | ニプロ株式会社 | Solid pharmaceutical composition containing a calcium blocker |
| JP6462625B2 (en) * | 2016-04-06 | 2019-01-30 | ニプロ株式会社 | Tablets containing calcium blockers |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59176247A (en) * | 1983-03-28 | 1984-10-05 | Taiyo Yakuhin Kogyo Kk | Method for preventing decomposition of water-soluble azunole |
| JPS6048960A (en) * | 1983-08-24 | 1985-03-16 | Kotobuki Seiyaku Kk | Azulene derivative, its preparation, and antitumor agent containing it as active ingredient |
| EP0450757A3 (en) * | 1990-02-22 | 1993-09-15 | Glaxo Group Limited | Use of 5-hydroxytryptamine-antagonists in the treatment of mental disorders originating in childhood |
| JP2594395B2 (en) * | 1991-11-27 | 1997-03-26 | 吉富製薬株式会社 | Stabilization method and formulation of sodium azulene sulfonate |
| JP3977724B2 (en) * | 2001-11-06 | 2007-09-19 | ロート製薬株式会社 | Pharmaceutical composition |
| JP4174300B2 (en) * | 2001-11-13 | 2008-10-29 | 壽製薬株式会社 | Rapidly disintegrating tablet or orally disintegrating tablet containing L-glutamine and sodium azulenesulfonate and method for producing the same |
| JP2003160484A (en) * | 2001-11-27 | 2003-06-03 | Kotobuki Seiyaku Kk | Orally administrative preparation composition with mitigated bitterness |
| WO2006043336A1 (en) * | 2004-10-20 | 2006-04-27 | Kotobuki Pharmaceutical Co., Ltd. | Therapeutic or preventive composition for gastric mucosa disease |
-
2008
- 2008-11-12 JP JP2008289702A patent/JP5465867B2/en active Active
-
2009
- 2009-11-10 KR KR1020090107814A patent/KR101627860B1/en active IP Right Grant
- 2009-11-12 CN CN2009102260483A patent/CN101732290B/en not_active Expired - Fee Related
-
2010
- 2010-09-27 HK HK10109226.5A patent/HK1142806A1/en not_active IP Right Cessation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102861337B (en) * | 2012-03-26 | 2017-08-11 | 北京阜康仁生物制药科技有限公司 | One kind contains solid formulation of egualen sodium |
Also Published As
| Publication number | Publication date |
|---|---|
| KR101627860B1 (en) | 2016-06-07 |
| HK1142806A1 (en) | 2010-12-17 |
| KR20100053449A (en) | 2010-05-20 |
| JP2010116337A (en) | 2010-05-27 |
| JP5465867B2 (en) | 2014-04-09 |
| CN101732290B (en) | 2013-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220183987A1 (en) | Pharmaceutical compositions of pimobendan | |
| KR101159617B1 (en) | Tablet quickly disintegrating in oral cavity | |
| CN102138903B (en) | Everolimus solid oral medicinal composition | |
| EP3154529B1 (en) | Orally disintegrating tablet containing solid lipid particles and methods for their preparation and use | |
| TWI659752B (en) | Oral administration preparations masking the bitter taste of silodosin | |
| CN101732290B (en) | Stable solid formulation of egualen sodium | |
| US8753682B2 (en) | Dual release oral tablet compositions of dexlansoprazole | |
| KR20030081489A (en) | Utilization of spray-dried powder containing sugar alcohol | |
| KR100908418B1 (en) | Quinolinone derivative pharmaceutical composition and preparation method thereof | |
| JP4963846B2 (en) | Orally disintegrating tablet and method for producing the same | |
| WO2019151405A1 (en) | Tablets and method for producing same | |
| JPWO2007049626A1 (en) | Cabergoline-containing oral solid preparation | |
| CN105641701A (en) | Stable nystatin medicine composition and preparation method thereof | |
| KR20130062691A (en) | Rapid solid dispersion oral compsition for using wheat bran | |
| US11576929B2 (en) | Composition for inflammatory gastrointestinal disorders | |
| WO2013062073A1 (en) | Orally disintegrating tablet containing low-dose ramosetron | |
| EP2384747A2 (en) | Oral Tablet Compositions Of Dexlansoprazole | |
| CN102861337B (en) | One kind contains solid formulation of egualen sodium | |
| JP2023119588A (en) | Solid preparation comprising loxoprofen and glycine and method for producing the same | |
| JP2022074105A (en) | Linagliptin-containing granule and pharmaceutical composition | |
| JP5878510B2 (en) | Stable eguarene sodium solid formulation | |
| CN101637443A (en) | Solid preparation containing cysteine with reduced smell | |
| KR20050121497A (en) | Pharmaceutical compositions and the methods of an oral preparation of itraconazole |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1142806 Country of ref document: HK |
|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1142806 Country of ref document: HK |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130828 Termination date: 20151112 |
|
| EXPY | Termination of patent right or utility model |